US 12,404,297 B2
Salts and crystal forms of GABA-A positive allosteric modulator
Nelson B. Olivier, Stoughton, MA (US); Kiran Reddy, Charlestown, MA (US); Gabriel Martinez Botella, Wayland, MA (US); Magnus Ronn, Melrose, MA (US); and Paul A. Laskar, Napa, CA (US)
Assigned to PRAXIS PRECISION MEDICINES, INC., Boston, MA (US)
Filed by Praxis Precision Medicines, Inc., Boston, MA (US)
Filed on Dec. 5, 2023, as Appl. No. 18/529,117.
Application 18/529,117 is a continuation of application No. 17/143,602, filed on Jan. 7, 2021, abandoned.
Application 17/143,602 is a continuation of application No. 16/698,057, filed on Nov. 27, 2019, granted, now 10,927,141, issued on Feb. 23, 2021.
Application 16/698,057 is a continuation of application No. 16/517,369, filed on Jul. 19, 2019, granted, now 10,562,930, issued on Feb. 18, 2020.
Claims priority of provisional application 62/725,805, filed on Aug. 31, 2018.
Prior Publication US 2024/0140985 A1, May 2, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. C07J 43/00 (2006.01); A61K 9/20 (2006.01); A61K 31/4164 (2006.01); C07D 233/60 (2006.01)
CPC C07J 43/003 (2013.01) [A61K 9/20 (2013.01); A61K 31/4164 (2013.01); C07B 2200/13 (2013.01)] 17 Claims
 
1. A method of treating a disease or condition selected from epilepsy, bipolar disorder, and anxiety, the method comprising administering to a patient in need thereof an effective amount of a pharmaceutical composition comprising crystalline Form A of the citrate salt of 3α-hydroxy-3α-methoxymethyl-21-(1′-imidazolyl)-5α-pregnan-20-one, wherein the crystalline Form A exhibits an X-ray powder diffraction (XRPD) pattern comprising peaks at 5.7±0.2, 12.5±0.2 and 20.1±0.2 degrees two-theta using copper K-alpha radiation.